Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate, but not every enlarged prostate causes urinary obstruction or symptoms. The decision to treat is based not only on prostate volume, but on how symptoms affect quality of life, urinary flow, post-void residual urine, prostate anatomy, bladder function, and the patient's priorities.
Last medical review: 2026
What do LUTS, BPH, BPE and BPO mean?
These related terms are often used loosely but mean different things. LUTS (lower urinary tract symptoms) is an umbrella term for storage, voiding, and post-voiding symptoms and does not by itself indicate a specific cause. BPH (benign prostatic hyperplasia) refers specifically to benign cellular growth in the prostate — primarily a histological term. BPE (benign prostatic enlargement) refers to prostate volume being large on examination or imaging. BPO (benign prostatic obstruction) refers to bladder outlet obstruction caused by the prostate, which may be distinguished from poor bladder muscle contractility using pressure-flow studies when needed. A large prostate does not always cause severe symptoms, and a smaller prostate can still cause significant obstruction depending on its anatomy.
Symptoms of BPH
Symptoms fall into three groups. Storage symptoms include frequent urination, urgency, nighttime urination, and urgency incontinence. Voiding symptoms include hesitancy, a weak or intermittent stream, straining, a split stream, and prolonged urination. Post-voiding symptoms include a sense of incomplete emptying and post-void dribbling. The type and severity of symptoms do not, by themselves, indicate the degree of true obstruction — urgency and nighttime urination in particular can also relate to an overactive bladder, sleep apnea, cardiovascular disease, fluid retention, diabetes, or excess nighttime urine production.
When should symptoms be evaluated urgently?
Complete inability to urinate or a painfully full bladder, visible blood clots in the urine, fever and chills with urinary symptoms, severe flank pain with nausea or vomiting, recurrent urinary infection, declining kidney function, or unexplained weight loss and significant fatigue should be evaluated promptly rather than attributed to BPH alone.
How is BPH diagnosed?
Evaluation is tailored to the patient and typically includes a symptom and quality-of-life assessment, medication review and physical examination, urinalysis, PSA testing when relevant to the individual's risk and decision-making, creatinine/eGFR when kidney involvement is suspected, ultrasound to assess prostate volume, the kidneys, and post-void residual urine, uroflowmetry, and, in select patients, a bladder diary, cystoscopy, or urodynamic testing. Prostate MRI is not a routine test for BPH and is generally reserved for suspected prostate cancer or another specific indication.
Can BPH raise PSA?
Yes, PSA can rise as prostate volume increases. However, an elevated PSA should never be attributed to BPH alone — age, infection, recent procedures, and the possibility of prostate cancer must be considered together, along with prostate volume, the PSA trend over time, examination, and imaging when indicated.
Does every enlarged prostate need treatment?
No. Mild to moderate symptoms that do not significantly affect quality of life and show no signs of complications can often be managed with observation and lifestyle changes, such as adjusting the timing rather than simply reducing fluid intake, moderating caffeine and alcohol, preventing constipation, and practicing relaxed or double voiding. Prostate volume alone is not a reason for surgery — it mainly helps determine which medication or procedure would be most suitable if treatment is needed.
Medication options
Alpha-blockers can relieve symptoms quickly but do not shrink the prostate or, on their own, reduce long-term progression risk; dizziness, low blood pressure, and ejaculatory changes can occur. 5-alpha-reductase inhibitors act over months in patients with enlarged prostates and progression risk, and can reduce prostate volume, retention risk, and surgical risk, but may affect libido, erectile, and ejaculatory function, and alter PSA interpretation. Combination therapy may be considered for moderate-to-severe symptoms with progression risk, at the cost of a higher combined side-effect burden. Antimuscarinics and beta-3 agonists can help when storage symptoms predominate, and PDE5 inhibitors may help suitable patients with LUTS and coexisting erectile dysfunction, though they cannot be combined with nitrates.
When is surgery or a procedure needed?
Surgery is generally considered for recurrent or treatment-resistant urinary retention, overflow incontinence, recurrent infection, bladder stones or a bladder diverticulum, BPH-related bleeding resistant to treatment, or upper urinary tract dilation or kidney function impairment. It may also be considered when quality-of-life-limiting symptoms persist despite observation and medication, or when a patient cannot or does not wish to continue medication. The choice of technique depends on prostate volume and anatomy, presence of a middle lobe, bladder function, blood thinner use, anesthesia risk, the importance placed on preserving ejaculation, likelihood of needing retreatment, and the surgeon's experience with the specific technique.
Comparing surgical and procedural options
TURP offers well-established, robust symptom and flow improvement for prostates roughly 30–80 mL, removing tissue with a meaningful chance of affecting ejaculation. HoLEP and ThuFLEP are laser enucleation techniques that can be applied largely independent of prostate size, offering durable results as an alternative to TURP and open surgery, though retrograde ejaculation is common with the standard technique — see our dedicated HoLEP and ThuFLEP guides. Rezūm water vapor therapy does not remove tissue and may better preserve ejaculatory function, though its objective flow improvement is generally less pronounced — see our Rezūm guide. UroLift/PUL and Aquablation are additional options with their own suitability criteria, ejaculation-preservation profiles, and retreatment rates that should be discussed individually. Open or robotic simple prostatectomy may be considered for very large glands, generally over 80 mL, when endoscopic enucleation is not available or suitable.
Does treatment affect urinary control and sexual function?
Temporary urgency or stress-type leakage can occur early after enucleation surgery and generally improves during recovery, though persistent incontinence, while uncommon, is not impossible. Erectile function is preserved in most patients after enucleation techniques, broadly comparable to TURP, but reduced or absent antegrade ejaculation is common after tissue-removing procedures — this is distinct from loss of erection, and orgasmic sensation often continues. Rezūm and UroLift/PUL are associated with a higher likelihood of preserving ejaculation, though this cannot be guaranteed for any individual patient.
Frequently asked questions
Is prostate enlargement cancer?
No. Benign prostatic hyperplasia is not cancer. Because BPH and prostate cancer can coexist in the same patient, PSA, examination, and additional testing when needed are evaluated based on the clinical picture.
Does BPH turn into prostate cancer?
BPH is not considered to progress into prostate cancer. It remains important, however, not to attribute urinary symptoms to BPH alone without appropriate cancer-related evaluation.
Does a large prostate always require surgery?
No. Prostate volume alone is not a reason for surgery. The decision is based on symptoms, quality of life, obstruction, post-void residual urine, kidney/bladder effects, and the patient's preferences.
Which procedure is right for me?
The right approach depends on prostate volume and anatomy, bladder function, blood thinner use, anesthesia risk, how much you prioritize preserving ejaculation, and the surgeon's experience — all of which are considered together during evaluation.
Source: European Association of Urology (EAU) Guidelines on the Management of Non-neurogenic Male LUTS, 2026. This content is for general information only and does not replace individualized medical evaluation. Prepared and medically reviewed by Professor Cenk Acar, Urologist.